FLORENCE, ITALY, May 22, 2023, A.Menarini Diagnostics S.r.l. (Menarini) is pleased to announce the commercial launch of its PRIME MDx platform: a sample-to-result, all-in-one, fully-automated molecular diagnostics platform for the processing of various testing portfolios through real-time PCR.

Hamburg, Germany, 2 - 6 October 2023

European Congress of Clinical Microbiology and Infectious Diseases

Barcelona, 27 - 30 April 2024

booth D17

Florence, Italy, 9 September 2024 - A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. 

Florence, Italy - 3rd December 2024.  A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.